EFTA02592815

From: A Barrett Sent: Wednesday, October 8, 2014 10:46 PM To: Jeffrey E. Subject: Re: Confidential: Early detection of Ebola Thanks for your help Anth=ny Barrett On Oct 8, 2014, at 6:32 PM, "jeffre= E." <[email protected] <mailto:[email protected]> =gt; wrote: ill=try, also i started the conversatoin with mark about splitting u= the interest, he is open to the idea, but wanted someone=smart to advise. that meanss he does't want to pay for advice. On Wed, Oct 8, 2=14 at 6:28 PM, A Barrett Hi Jeffrey, mailto > wrote: =ny interest in helping on this. I know last time you and Francis did not hi= it off. Nevertheless he has been successful as a scientist and is really n=t a "people' person. Foundation. He claims he can devel=p the tools to diagnose Ebola before it becomes symtomatic. Anthony Barrett Begin forwa=ded message: From: Franc=s Barany < Date: October 8, 2014 at 6:06:32 PM E=T To: Anthony Barrett < Cc: Michael Gargano animagonflialmina Subject: Confidential: Early detection of Ebola<=b> Dear Anthony, I really appreciate your willingness to find a potential pathway to Bil= Gates and the Gates EFTA_R1_01775910 EFTA02592815 By way of introduction, I have been a Professor at Weill-Cornell for th= last 30 years, and am best known for having invented the Ligase C=ain Reaction (ICR) and the Universal Array. I hold 46 issued US p=tents, a number of which have led to commercial tests to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, C0=NSR for NIPD of trisomy), and identify diseases using DNA microarrays a=d targeted Next-Gen sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=. I have been collaborating with Dr. Linnie Golightly of our Center for G=obal Health/Infectious Disease Division for the past decade, work=ng together closely to develop multiplexed PCR-LDR assays for Category=A Biothreat agents, including all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Congo=nbsp;hemorrhagic fever virus, Lassa fever virus, Rift Valley fever vir=s, Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manuscript just being submitted). In addition, in collaboration with Professor Soper at UNC, we have been building =icro-fabricated devices to rapidly detect pathogens. Most recently, we have begun designing micro-fabricated devices that wi=l allow for electronic detection, obviating the need for expensiv= hardware used in most fluorescent detection schemes (i.e. Taqman assa=s). As such, we are poised to combine these technologies for rapidly identifying and providing quantitative viral load for=all the VHF, Variola, Malaria or other Category A pathogens directly f=om a drop of blood, with the next level of such devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device. • Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious. • Next level of assay needs to b=> 100-fold more sensitive. We know how to address this issue. • This would allow for identifi=ation of individuals with early viral replication in their blood •=94before they are contagious, so they may be isolated, and further,&nb=p;early detection may improve outcomes. Would your contacts be able to help us, so in turn we may help protect o=r country? Most appreciated, Francis & Linnie Dr. Francis Barany Dept of Microbiology & Immunology Box 62 Rm B-406 Linnie Golightly, MD Associate Professor of Clinical Medicine and Microbiology & Immunology Center for Global Health Division of Infectious Diseases Weill Cornell Medical College 2 EFTA_R1_01775911 EFTA02592816 A Multiplex PCR/LDR Assay for the Simultaneous Identification of C=tegory A Infectious Pathogens: Agents of Viral Hemorrhagic Fever and V=riola Virus Das 5.1, Rundell M.S.2, Mirza A.H.2, Pingle M.R.2, Shigyo K.1, Garrison=A.R.3, Paragas J.4, Smith S. K.5, Olson V. A.5, Larone D.H.2, 6,&=bsp;Spitzer E.D.7, Barany F.2 and Golightly L.M.1, 2 1. Department of Medicine, Division of Infectious Diseases, Weill Medic=l College of Cornell University, New York, NY 2. Department of Microbiology and Immunology, Weill Medical College of C=rnell University, New York, NY 3. United States Army Medical Research Institute of Infectious Diseases= Frederick, MD. 4. Integrated Research Facility, Division of Clinical Research, N=AID, NIH, Ft. Detrick, MD 5. Poxvirus Team, Poxvirus and Rabies Branch, Division of High Conseque=ce Pathogens and Pathology, National Center of Emerging Zoonotic a=d Infectious Diseases, Centers for Disease Control and Prevention,&nbs=;Atlanta, GA 6. Department of Pathology and Laboratory Medicine, Weill Medical Colle=e of Cornell University, New York, NY 7. Department of Pathology, Stony Brook University Medical Center, Ston= Brook, NY ABSTRACT CDC designated category A infectious agents pose a major risk to nation=l security and require special action for public health prep=redness. They include viruses that cause viral hemorrhagic fever=(VHF) syndrome as well as variola virus, the agent of smallpox. VHF is characterized by hemorrhage and fever with multi- organ&nb=p;failure leading to high mortality and morbidity. Smallpox, a p=ior scourge, has been eradicated for decades making it a particul=rly serious threat if released nefariously in the essentially non-immu=e world population. Early detection of the causative agents a=d ability to distinguish them from other pathogens is essential to&nbs=;contain outbreaks, implement proper control measures and prevent morb=dity and mortality. We have developed a multiplex detection= assay that uses several species-specific PCR primers to generate ampli=ons from multiple pathogens; these are then targeted in a ligase d=tection reaction (LDR). The resultant fluorescently-labeled=ligation products are detected on a universal array enabling simultaneous identification of the pathogens. The assay was=evaluated on 32 different isolates associated with VHF (ebolavirus,&nb=p;marburgvirus Crimean Congo hemorrhagic fever virus, Lassa fever viru=, Rift Valley fever virus, Dengue virus, and Yellow fever virus) as well as variola virus and vaccinia virus (the agent of small=ox and its vaccine strain, respectively). The assay was abl= to detect all viruses tested including 8 sequences representative&nbs=;of different variola virus strains from the CDC repository. It does not cross react with other emerging zoonoses such a= monkeypox virus or cowpox virus, or six flaviviruses tested (St. Loui= encephalitis virus, Murray Valley Encephalitis virus, Powassan v=rus, Tick-borne encephalitis virus, West Nile virus and Japanese encephalitis virus). 3 EFTA_R1_01775912 EFTA02592817 please note =div>The information contained in this communication is confidential, may=be attorney-client privileged, may constitute inside information, and is=intended only for the use of the addressee. It is the property of JEE=br>Unauthorized use, disclosure or copying of this communication or any p=rt thereof is strictly prohibited and may be unlawful. If you have recei=ed this communication in error, please notify us immediately by retur= e-mail or by e-mail to [email protected] <mailto:[email protected]> , and destroy this communication and all=copies thereof, including all attachments. copyright -all rights reserve= 4 EFTA_R1_01775913 EFTA02592818